Want to see SLN full AI Analyst Report?
Silence Therapeutics (SLN) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sln360 | Cardiovascular Diseases, Atherosclerosis, Lipoprotein(A) | Phase II | Completed | Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events | Sep 06, 2022 | ― |
| Sln124 | Polycythemia Vera | phase1AndPhase2 | Recruiting | Study to Assess SLN124 in Patients With Polycythemia Vera | Jul 29, 2022 | ― |
| Sln124 | Non-Transfusion-Dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome | Phase I | Completed | A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome | Jan 19, 2021 | ― |
| Sln360 | Elevated Lp(A), Dyslipidemias, Hyperlipidemias | Phase I | Completed | Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) | Oct 07, 2020 | ― |
| Sln124 | Healthy Volunteers | earlyPhase1 | Completed | A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers | Sep 08, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sln360 | Phase II | Cardiovascular Diseases, Atherosclerosis, Lipoprotein(A) | Completed | Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events | Sep 06, 2022 | ― |
| Sln124 | phase1AndPhase2 | Polycythemia Vera | Recruiting | Study to Assess SLN124 in Patients With Polycythemia Vera | Jul 29, 2022 | ― |
| Sln124 | Phase I | Non-Transfusion-Dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome | Completed | A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome | Jan 19, 2021 | ― |
| Sln360 | Phase I | Elevated Lp(A), Dyslipidemias, Hyperlipidemias | Completed | Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) | Oct 07, 2020 | ― |
| Sln124 | earlyPhase1 | Healthy Volunteers | Completed | A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers | Sep 08, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Silence Therapeutics Plc (SLN) have in its pipeline
Silence Therapeutics SLN is currently developing the following drugs: Sln360, Sln124. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
